{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:40:16Z","timestamp":1792172416225,"version":"4.4.0"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Neonatal infections are associated with high morbidity and mortality rates. Optimal treatment of these infections requires knowledge of neonatal pharmacology and integration of neonatal developmental pharmacokinetics (PKs) of antimicrobial drugs in the design of dosing regimens for use with different gestational and postnatal ages. Population PK and pharmacodynamic models are used to personalize the use of these drugs in these fragile patients. The final step to further minimize variability in an individual patient is therapeutic drug monitoring (TDM), where the same population PK\/pharmacodynamic models are used in concert with optimally drawn blood samples to further fine-tune therapy. The purpose of this article is to describe the present status and future role of model-based precision dosing and TDM of antimicrobial drugs in neonates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed was searched for clinical trials or clinical studies of TDM in neonates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 447 articles were retrieved, of which 19 were concerned with antimicrobial drugs. Two articles (one aminoglycoside and one vancomycin) addressed the effects of TDM in neonates. We found that, in addition to aminoglycosides and vancomycin, TDM also plays a role in beta-lactam antibiotics and antifungal drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>There is a growing awareness that, in addition to aminoglycosides and vancomycin, the use of beta-lactam antibiotics, such as amoxicillin and meropenem, and other classes of antimicrobial drugs, such as antifungal drugs, may benefit from TDM. However, the added value must be shown. New analytical techniques and software development may greatly support these novel developments.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000919","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:38:32Z","timestamp":1628548712000},"page":"65-74","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Therapeutic Drug Monitoring of Antimicrobial Drugs in Neonates: An Opinion Article"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"Daan J.","family":"Touw","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen;"},{"name":"Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4028-9286","authenticated-orcid":false,"given":"John N.","family":"van den Anker","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Children's National Hospital, Washington, DC ;"},{"name":"Department of Paediatric Pharmacology and Pharmacometrics, University Children's Hospital, University of Basel, Basel, Switzerland; and"},{"name":"Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/jcph.1725","article-title":"Does \u201cbirth\u201d as an event impact maturation trajectory of renal clearance via glomerular filtration? Reexamining data in preterm and full-term neonates by avoiding the creatinine bias","volume":"61","author":"Salem","year":"2021","journal-title":"J Clin Pharmacol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00467-020-04749-3","article-title":"Characterizing dynamics of serum creatinine and creatinine clearance in extremely low birth weight neonates during the first 6 weeks of life","volume":"36","author":"van Donge","year":"2021","journal-title":"Pediatr Nephrol."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijerph18020662","article-title":"Amikacin or vancomycin exposure alters the postnatal serum creatinine dynamics in extreme low birth weight neonates","volume":"18","author":"van Donge","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.trac.2015.11.026","article-title":"LC-MS\/MS for therapeutic drug monitoring of anti-infective drugs","volume":"84","author":"Veringa","year":"2016","journal-title":"Trends Anal Chem."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dkv418","article-title":"The worldwide antibiotic resistance and prescribing in european children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children","volume":"71","author":"Versporten","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40262-018-0729-3","article-title":"Developmental pharmacokinetics and age-appropriate dosing design of milrinone in neonates and infants with acute kidney injury following cardiac surgery","volume":"58","author":"Mizuno","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","article-title":"Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children","volume":"45","author":"Johnson","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc1876","article-title":"The surviving sepsis campaign: raising awareness to reduce mortality","volume":"7","author":"Slade","year":"2003","journal-title":"Crit Care."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1197\/j.aem.2004.11.017","article-title":"A blueprint for a sepsis protocol","volume":"12","author":"Shapiro","year":"2005","journal-title":"Acad Emerg Med."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21165898","article-title":"Therapeutic drug monitoring is a feasible tool to personalize drug administration in neonates using new techniques: an overview on the pharmacokinetics and pharmacodynamics in neonatal age","volume":"21","author":"de Rose","year":"2020","journal-title":"Int J Mol Sci."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2146\/ajhp070314","article-title":"Two nomograms for determining extended-dosing intervals for gentamicin in neonates","volume":"65","author":"Murphy","year":"2008","journal-title":"Am J Health-syst Pharm."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/1120009X.2019.1599574","article-title":"Actual body weight-based vancomycin dosing in neonates","volume":"31","author":"Pokorn\u00e1","year":"2019","journal-title":"J Chemother."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40272-020-00400-8","article-title":"External validation of model-based dosing guidelines for vancomycin, gentamicin, and tobramycin in critically ill neonates and children: a pragmatic two-center study","volume":"22","author":"Hartman","year":"2020","journal-title":"Paediatr Drugs."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00007691-199610000-00005","article-title":"Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring","volume":"18","author":"Isemann","year":"1996","journal-title":"Ther Drug Monit."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"e20182179","DOI":"10.1542\/peds.2018-2179","article-title":"Continuous versus intermittent vancomycin infusions in infants: a randomized controlled trial","volume":"143","author":"Gwee","year":"2019","journal-title":"Pediatrics."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: how well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front Pharmacol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: a review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4155\/ipk-2018-0005","article-title":"Bayesian therapeutic drug monitoring software: past, present and future","volume":"3","author":"Drennan","year":"2018","journal-title":"\u200bInt J Pharmacokinet."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/01.ftd.0000211831.96102.91","article-title":"Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates","volume":"28","author":"Pullen","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"e00707","DOI":"10.1128\/AAC.00707-17","article-title":"Tools for the individualized therapy of teicoplanin for neonates and children","volume":"61","author":"Ramos-Mart\u00edn","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fphar.2020.00551","article-title":"Model-informed precision dosing of vancomycin in hospitalized children: implementation and adoption at an academic children's hospital","volume":"11","author":"Frymoyer","year":"2020","journal-title":"Front Pharmacol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-021-04288-0","article-title":"Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation","volume":"87","author":"Lawson","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40268-020-00302-7","article-title":"Assessment of vancomycin pharmacokinetics and dose regimen optimisation in preterm neonates","volume":"20","author":"Mulubwa","year":"2020","journal-title":"Drugs R D."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9343(02)01476-6","article-title":"Pharmacokinetic dosing of aminoglycosides: a controlled trial","volume":"114","author":"Bartal","year":"2003","journal-title":"Am J Med."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199121060-00006","article-title":"Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies","volume":"21","author":"Jelliffe","year":"1991","journal-title":"Clin Pharmacokinet."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/clpt.1988.142","article-title":"An evaluation of optimal sampling strategy and adaptive study design","volume":"44","author":"Drusano","year":"1988","journal-title":"Clin Pharmacol Ther."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF02353472","article-title":"Development of limited sampling strategies for characteristics of a pharmacokinetic profile","volume":"23","author":"Sallas","year":"1995","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/AAC.47.9.2888-2891.2003","article-title":"Optimal sampling schedule design for populations of patients","volume":"47","author":"Tam","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: an overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb Perspect Med."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"127218","DOI":"10.1016\/j.bmcl.2020.127218","article-title":"The relationship between the structure and toxicity of aminoglycoside antibiotics","volume":"30","author":"Jospe-Kaufman","year":"2020","journal-title":"Bioorg Med Chem Lett."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(86)90488-2","article-title":"Choice of drug and dosage regimen: two important risk factors for aminoglycoside nephrotoxicity","volume":"80","author":"de Broe","year":"1986","journal-title":"Am J Med."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/bmj.305.6866.1421","article-title":"ABC of monitoring drug therapy: aminoglycoside antibiotics","volume":"305","author":"Aronson","year":"1992","journal-title":"Br Med J."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"Int J Infect Dis."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/31.suppl_D.149","article-title":"Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man","volume":"31","author":"Craig","year":"1993","journal-title":"J Antimicrob Chemother."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/infdis\/149.3.443","article-title":"The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia","volume":"149","author":"Moore","year":"1984","journal-title":"J Infect Dis."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diagmicrobio.2005.02.011","article-title":"Pharmacodynamics of tobramycin in patients with cystic fibrosis","volume":"52","author":"Mouton","year":"2005","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/27.suppl_C.49","article-title":"Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin","volume":"27","author":"Tulkens","year":"1991","journal-title":"J Antimicrob Chemother."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000457685","article-title":"Population pharmacokinetics of gentamicin in neonates","volume":"11","author":"Thomson","year":"1988","journal-title":"Dev Pharmacol Ther."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00007691-200106000-00004","article-title":"Population kinetics of tobramycin in neonates","volume":"23","author":"Falc\u00e3o","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000014053","article-title":"Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit","volume":"74","author":"Langhendries","year":"1998","journal-title":"Biol Neonate."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1542\/peds.114.1.e111","article-title":"Extended-interval aminoglycoside administration for children: a meta-analysis","volume":"114","author":"Contopoulos-Ioannidis","year":"2004","journal-title":"Pediatrics."},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"R44-20250603","first-page":"98","article-title":"An extended-interval gentamicin dosage regimen in newborns\u202f: a prospective study","volume":"13","author":"Sum","year":"2007","journal-title":"Eur J Hosp Pharm."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jcph.190","article-title":"Impact of small-for-gestational age (sga) status on gentamicin pharmacokinetics in neonates","volume":"54","author":"Lulic-Botica","year":"2014","journal-title":"J Clin Pharmacol."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/phar.2376","article-title":"Executive summary: therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"40","author":"Rybak","year":"2020","journal-title":"Pharmacotherapy."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"106300","DOI":"10.1016\/j.ijantimicag.2021.106300","article-title":"Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing","volume":"57","author":"Tang","year":"2021","journal-title":"Int J Antimicrob Agents."},{"key":"R48-20250603","first-page":"1","article-title":"Population pharmacokinetics and dose optimization of vancomycin in neonates","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir078","article-title":"Vancomycin: we can't get there from here","volume":"52","author":"Patel","year":"2011","journal-title":"Clin Infect Dis."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis."},{"key":"R51-20250603","first-page":"A2667","article-title":"Continue en intermitterende infusie van vancomycine even effectief","volume":"155","author":"Van Maarseveen","year":"2011","journal-title":"Nederlands Tijdschrift voor Geneeskunde."},{"key":"R52-20250603","article-title":"Implementation of vancomycin therapeutic monitoring guidelines: focus on Bayesian estimation tools in neonatal and pediatric patients","author":"Han","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jac\/dkv288","article-title":"Is prolonged infusion of piperacillin\/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic\/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort","volume":"71","author":"Abdul-Aziz","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jac\/dkl478","article-title":"Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study","volume":"59","author":"Roberts","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2015.06.002","article-title":"Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization","volume":"24","author":"Sime","year":"2015","journal-title":"Curr Opin Pharmacol."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-4781-x","article-title":"The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial","volume":"20","author":"Abdulla","year":"2020","journal-title":"BMC Infect Dis."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1684\/epd.2016.0875","article-title":"Amoxicillin, a potential epileptogenic drug","volume":"18","author":"Raposo","year":"2016","journal-title":"Epileptic Disord."},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/27.4.405","article-title":"Neurotoxicity of \u03b2-lactam antibiotics: predisposing factors and pathogenesis","volume":"27","author":"Schliamser","year":"1991","journal-title":"J Antimicrob Chemother."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkaa468","article-title":"Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study","volume":"76","author":"Wu","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.630047","article-title":"Population pharmacokinetic study of cefathiamidine in infants with augmented renal clearance","volume":"12","author":"Du","year":"2021","journal-title":"Front Pharmacol."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1159\/000509751","article-title":"Amoxicillin dosing regimens for the treatment of neonatal sepsis: balancing efficacy and neurotoxicity","volume":"117","author":"van Donge","year":"2021","journal-title":"Neonatology."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00228-012-1413-4","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in neonates and young infants","volume":"69","author":"Li","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/FTD.0b013e3182587665","article-title":"Population pharmacokinetics of piperacillin using scavenged samples from preterm infants","volume":"34","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/jac\/dky128","article-title":"Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies","volume":"73","author":"Germovsek","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00007691-200106000-00003","article-title":"Pharmacokinetics of meropenem in preterm neonates","volume":"23","author":"van Enk","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2133\/dmpk.DMPK-11-RG-027","article-title":"Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic\/pharmacodynamic considerations","volume":"26","author":"Ohata","year":"2011","journal-title":"Drug Metab Pharmacokinet."},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1128\/AAC.00351-09","article-title":"Meropenem pharmacokinetics in the newborn","volume":"53","author":"van den Anker","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J Clin Pharmacol."},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.jp.7211532","article-title":"Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight","volume":"26","author":"Frankenbusch","year":"2006","journal-title":"J Perinatol."},{"key":"R70-20250603","first-page":"19","article-title":"Combination antifungal therapy with voriconazole for persistent candidemia in very low birth weight neonates","volume":"53","author":"Turan","year":"2011","journal-title":"Turk J Pediatr."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/tropej\/fmr025","article-title":"A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants","volume":"58","author":"Wahab mohamed","year":"2012","journal-title":"J Trop Pediatr."},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40262-016-0379-2","article-title":"Pediatric clinical pharmacology of voriconazole: role of pharmacokinetic\/pharmacodynamic modeling in pharmacotherapy","volume":"55","author":"Kadam","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijid.2011.06.004","article-title":"Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients","volume":"15","author":"Kim","year":"2011","journal-title":"Int J Infect Dis."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bcp.13151","article-title":"The effect of inflammation on voriconazole trough concentrations in children","volume":"83","author":"ter Avest","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/mmy\/myz006","article-title":"Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients","volume":"57","author":"Lempers","year":"2019","journal-title":"Med Mycol."},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/INF.0000000000002959","article-title":"Rare infant case of pulmonary aspergilloma highlighting common challenges with voriconazole dosing","volume":"40","author":"Abo","year":"2021","journal-title":"Pediatr Infect Dis J."},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.00474-06","article-title":"Association of fluconazole area under the concentration-time curve\/MIC and dose\/MIC ratios with mortality in nonneutropenic patients with candidemia","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1128\/AAC.49.8.3171-3177.2005","article-title":"Fluconazole MIC and the fluconazole dose\/MIC ratio correlate with therapeutic response among patients with candidemia","volume":"49","author":"Clancy","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"R80-20250603","first-page":"115","article-title":"Review of fluconazole treatment and prophylaxis for invasive candidiasis in neonates","volume":"26","author":"Hornik","year":"2021","journal-title":"J Pediatr Pharmacol Ther."},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-012-1468-2","article-title":"Safety of fluconazole in paediatrics: a systematic review","volume":"69","author":"Egunsola","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00007691-200010000-00022","article-title":"Fluconazole-induced convulsions at serum trough concentrations of approximately 80 microg\/mL","volume":"22","author":"Matsumoto","year":"2000","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:29:17Z","timestamp":1748971757000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000919","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-05-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}